Amarin Corp Plc (AMRN)

[HinduKush]

LaurentM

They argued that lowering trigs, even without raising LDL-C, was no big deal (said Lovaza + Statins was good enough) and said the commercial incentive was largely driven by the cardiovascular angle. This was in their attempt to downplay longfelt unmet need and delink the nexus to commercial success. If lowering trigs without raising LDL-C is no big deal, why bother going after Vascepa? Oh right, the backdoor into Reduce it.

Good point--very revealing.
Infringement is what infringement does....
If generics goal is to provide an economic therapy for treating high TG and reduce risk of pancreatitis:
Lets count the ways one could lower TG>500 to prevent "pancreatitis"
++Vascepa
++Statin (plus Lovaza)
++Fibrates eg Pemafibrate
++Nicotinic acid
++Lovaza
++Epanova
++Medium chain TG's
++Antisense oligonucleotides to ApoC3
++Antisense oligonucleotides to ANGPTL3
++Plasmapharesis

No doubt where they think their market will be once their product is launched. Third party payors know this and de facto promote the infringement by paying only for the generic product irrespective of the indication...
HK